Philips Unveils SmartIQ with Over 50% X-Ray Dose Reduction for Coronary Imaging
Philips launched SmartIQ technology for its Azurion image-guided therapy platform, featuring an ultra-low dose protocol that cuts X-ray exposure by over 50% in coronary procedures. The first blinded clinical pilot study demonstrated superior image quality and dose reduction, while the RADIQAL trial has reached 60% enrollment.
1. SmartIQ Technology Breakthrough
SmartIQ integrates an advanced processing algorithm into the Azurion platform, enabling an ultra-low dose protocol that reduces X-ray radiation by over 50% compared with the lowest settings on the previous ClarityIQ system. This enhancement delivers contrast-rich images with reduced noise, aiming to improve procedural precision for interventional cardiologists.
2. Strengthening Clinical Evidence
The first blinded clinical pilot study of SmartIQ showed the algorithm outperformed standard protocols in image quality assessments while maintaining or lowering both radiation and contrast dose. Concurrently, the RADIQAL randomized trial has reached 60% enrollment across European sites, setting the stage for definitive data on procedural performance and dose metrics.
3. Market Deployment and Outlook
SmartIQ is CE-marked and available now in Europe and selected markets on both new and existing Azurion systems, with demonstrations scheduled at EuroPCR 2026. Pending regulatory clearance in other regions, broader adoption could drive a significant uptick in Azurion system sales and reinforce Philips’ leadership in image-guided therapy.